One Year After Japan Paves Way, Follow-on Biologics Start Blossoming
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March
You may also be interested in...
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan